Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHull, M.en
dc.contributor.authorCharnock-Jones, D.en
dc.contributor.authorChan, C.en
dc.contributor.authorBruner-Tran, K.en
dc.contributor.authorOsteen, K.en
dc.contributor.authorTom, B.en
dc.contributor.authorFan, T.P.en
dc.contributor.authorSmith, S.en
dc.identifier.citationThe journal of Clinical Endocrinology and Metabolism, 2003; 88(6):2889-2899en
dc.description.abstractEndometriosis is a disease in which the lining of the uterus (endometrium), shed at the time of menstruation, becomes established at sites such as the peritoneum and ovaries. These explants develop a rich blood supply that enables them to survive and grow. We hypothesized that inhibitors of angiogenesis would prevent this growth by disrupting sensitive vessels supplying endometriotic lesions. Vessels sensitive to angiogenic antagonism have few associations with pericyte cells. The vessels supplying human endometriotic lesions were immunohistochemically characterized and found to be predominantly pericyte free. A model in which human endometrium is implanted into nude mice was used to test the effects of two antagonists of the angiogenic growth factor, vascular endothelial cell growth factor A. Soluble truncated receptor (flt-1; P = 0.002) and an affinity-purified antibody to human vascular endothelial cell growth factor A (P = 0.03) significantly inhibited the growth of nude mouse explants. Pericyte-free vessels were shown to supply endometrial lesions in nude mice and were disrupted in lesions taken from soluble flt-1-treated mice. In summary, antiangiogenic agents inhibited the growth of explants in an in vivo model of endometriosis by disrupting the vascular supply, and this effect is likely to apply to the human disease. These findings suggest that antiangiogenic agents may provide a novel therapeutic approach for the treatment of endometriosis.en
dc.description.statementofresponsibilityM. Louise Hull, D. Stephen Charnock-Jones, Clement L. K. Chan, Kaylon L. Bruner-Tran, Kevin G. Osteen, Brian D. M. Tom, Tai-Ping D. Fan, and Stephen K. Smithen
dc.publisherThe Endocrine Societyen
dc.rightsCopyright © 2003 by The Endocrine Societyen
dc.subjectEndometrium; Blood Vessels; Animals; Humans; Mice; Mice, Nude; Rats; Rats, Wistar; Endometriosis; Vascular Endothelial Growth Factor Receptor-1; Angiogenesis Inhibitors; Intercellular Signaling Peptides and Proteins; Vascular Endothelial Growth Factors; Vascular Endothelial Growth Factor A; Endothelial Growth Factors; Antibodies; Lymphokines; Solubility; Femaleen
dc.titleAntiangiogenic agents are effective inhibitors of endometriosisen
dc.typeJournal articleen
dc.identifier.orcidHull, M. [0000-0003-1813-3971]en
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.